CN117999254A - 水溶性前药、偶联物及其用途 - Google Patents

水溶性前药、偶联物及其用途 Download PDF

Info

Publication number
CN117999254A
CN117999254A CN202280053086.7A CN202280053086A CN117999254A CN 117999254 A CN117999254 A CN 117999254A CN 202280053086 A CN202280053086 A CN 202280053086A CN 117999254 A CN117999254 A CN 117999254A
Authority
CN
China
Prior art keywords
moiety
conjugate
compound
cancer
oligo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053086.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·沙巴特
R·萨特奇-法纳洛
S·斯维尼-拉什
C·德伊世
N·伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Original Assignee
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Ramot at Tel Aviv University Ltd filed Critical Merck Patent GmbH
Publication of CN117999254A publication Critical patent/CN117999254A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280053086.7A 2021-07-28 2022-07-20 水溶性前药、偶联物及其用途 Pending CN117999254A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL285208 2021-07-28
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CN117999254A true CN117999254A (zh) 2024-05-07

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053086.7A Pending CN117999254A (zh) 2021-07-28 2022-07-20 水溶性前药、偶联物及其用途

Country Status (7)

Country Link
EP (1) EP4377292A1 (https=)
JP (1) JP2024532677A (https=)
CN (1) CN117999254A (https=)
AU (1) AU2022318483A1 (https=)
CA (1) CA3226393A1 (https=)
IL (1) IL310354A (https=)
WO (1) WO2023007481A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701128YA (en) * 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN120682290A (zh) * 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
JP7708662B2 (ja) * 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法

Also Published As

Publication number Publication date
EP4377292A1 (en) 2024-06-05
IL310354A (en) 2024-03-01
AU2022318483A1 (en) 2024-02-22
JP2024532677A (ja) 2024-09-10
WO2023007481A1 (en) 2023-02-02
CA3226393A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7844499B2 (ja) 抗体－免疫アゴニストコンジュゲート及びその使用
CN113766954A (zh) 喜树碱衍生物
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
KR20230074119A (ko) 펩타이드 기반 링커
KR20240120744A (ko) 캄프토테신 화합물 및 이의 접합체
AU2018265333C1 (en) Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
EP4429707B1 (en) ANTHRACYCLINE-DERIVED BINDING REAGENTS, ANTIBODY-DRUG CONJUGATES AND PROCESSES
CN113941007A (zh) 一种串联的双药物链接组装单元及其应用
JP2025523117A (ja) リンカー、コンジュゲート及びその用途
TW202506105A (zh) 連接子－藥物分子及抗體藥物偶聯物、其製備方法和應用
CN117999254A (zh) 水溶性前药、偶联物及其用途
CN109790178B (zh) 新颖细胞毒性剂和其缀合物
JP2025538619A (ja) 抗腫瘍化合物及びその応用
HK40111022A (zh) 水溶性前药、偶联物及其用途
WO2025031923A1 (en) Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
WO2024207177A9 (en) Antibody, linkers, payload, conjugates and applications thereof
AU2016226083A1 (en) Cyclic peptide analogs and conjugates thereof
WO2023231988A1 (zh) 一种药物连接体偶联物的制备方法及其中间体
WO2025077572A1 (zh) 一种用于前药给药系统的可裂解连接体化合物及其制备和应用
CA3137125C (en) Camptothecin derivatives
WO2026062219A1 (en) Antibody-drug conjugates of vincristine, processes for preparing the same and uses thereof
KR20250057675A (ko) 캄프토테신 유도체를 포함하는 항-Tissue factor 항체-약물 접합체
CN121449623A (zh) 一种拓扑异构酶抑制剂及其偶联物的应用
KR20250057677A (ko) 캄프토테신 유도체를 포함하는 항-Nectin-4 항체-약물 접합체
TW202613076A (zh) 鏈接子－有效負載、由其作成之抗體－藥物共軛物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111022

Country of ref document: HK